2017 (7 POSTS)

Finley BL, Donovan ED, Kovochich M, Paustenbach DJ, Urban AM. Perineal use of cosmetic talc as a risk factor for ovarian cancer: A weight-of-evidence evaluation. Abstract #1288. Poster presentation at Society of Toxicology 56th Annual Meeting, Baltimore, MD, 2017.

Suh M, Harvey S, Wikoff D, Mittal L, Ring C, Goodmanson A, Proctor D. Meta-analysis of hexavalent chromium and stomach cancer. Poster presented at Society of Toxicology 56th Annual Meeting, March 13, Baltimore, MD, March 2017.

View Abstract

Finley BL, Benson SM, Marsh GM. 2017. Cosmetic talc as a risk factor for pleural mesothelioma: A weight of evidence evaluation of the epidemiology. Inhal Toxicol 29(4):179–185; doi: 10.1080/08958378.2017.1336187. PMID: 28651470.

 

View Abstract

2016 (27 POSTS)

Cui Y, Li J, Weng L, Wirbisky SE, Freeman JL, Liu J, Liu Q, Yuan X, Irudayaraj J. 2016. Regulatory landscape and clinical implication of MBD3 in human malignant glioma. Oncotarget 7(49):81698–81714; doi: 10.18632/oncotarget.13173. PMID: 27835581.

View Abstract

Wikoff D, Suh M, Harvey S, Proctor D, Beretvas T, Goodman M, Lipworth L. 2016. Systematic review and meta-analysis of occupational exposure to Cr(VI) and stomach cancer. PROSPERO 2016:CRD42016051625 Available from http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016051625

Garabrant DH, Alexander DD, Miller PE, Fryzek JP, Boffetta P, Teta MJ, Hessel PA,.., Kelsh MA, et al. 2016. Response to Kay Teschke. Re: Mesothelioma among motor vehicle mechanics: An updated review and meta-analysis. Ann Occup Hyg 60(8):1036-1037; doi: 10.1093/annhyg/mew038. PMID: 27328807.

View Abstract

Gökbuget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H, et al. 2016. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J 6(9):e473; doi: 10.1038/bcj.2016.84. PMID: 27662202.

View Abstract

Bi P, Yue F, Karki A, Castro B, Wirbisky SE, Wang C, … Kuang, S. 2016. Notch activation drives adipocyte dedifferentiation and tumorigenic transformation in mice. J Exp Med 213(10):2019–2037; doi: 10.1084/jem.20160157. PMID: 27573812.

View Abstract

Lowe KA, Danese MD, Gleeson ML, Langeberg WJ, Kelsh MA. 2016. Racial and ethnic variability in the prevalence and incidence of comorbidities associated with gastric cancer in the United States. J Gastrointest Cancer 47(2):168–181; doi: 10.1007/s12029-016-9809-5.

View Abstract

Hummel HD, Topp MS, Chang ET, Chia VM, Kelsh MA, Doemland ML, et al. 2016. Adverse events in adults with relapsed or refractory acute lymphoblastic leukemia (ALL): A literature review of recent clinical trials. J Leuk 4(1):208; doi: 10.4172/2329-6917.1000208.

View Abstract

Erichsen R, Kelsh MA, Oliner KS, Nielsen KB, Frøslev T, Lænkholm AV, et al. 2016. Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: A Danish cohort study. Annals of Epidemiol 26(7):500–503; doi: 10.1016/j.annepidem.2016.05.002. PMID: 27318530.

View Abstract

Gökbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, … Kelsh M, et al. 2016. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica 101(12):1524–1533; doi: 10.3324/haematol.2016.144311. PMID: 27587380.

View Abstract

Pierce JS, Ruestow PS, Finley BL. 2016. An updated evaluation of reported no-observed adverse effect levels for chrysotile asbestos for lung cancer and mesothelioma. Crit Rev Toxicol 46(7):561-586; doi: 10.3109/10408444.2016.1150960. PMID: 27031024.

View Abstract

Suh M, Thompson CM, Brorby GP, Mittal L, Proctor DM. 2016. Inhalation cancer risk assessment of cobalt metal. Regul Toxicol Pharm 79(Aug):74-82; doi: 10.1016/j.yrtph.2016.05.009. PMID: 27177823.

View Abstract

Panko JM, Benson SM, Kreider ML. Meta-analysis of lung cancer risk related to diesel exposure by occupation and evaluation of exposure response. Abstract #2976. Poster at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.

View Abstract

Lancet JE, Sacks NC, Cyr PL, Chiarella MT, Louie AC, Cortes JE. VYXEOS™ (CPX-351) increases event-rree survival and time spent out of the hospital in acute myeloid leukemia patients, compared with 7+3 standard of care. Academy of Managed Care & Specialty Pharmacy Annual Meeting, San Francisco CA, April 2016.

Sacks NC, Noone J, Cyr PL, Miller DJ, Chiarella MT, Louie AC. Hospitalizations for older patients with acute myeloid leukemia (AML): High costs and long stays, with and without chemotherapy. Academy Health Annual Research Meetings, Boston, MA, 2016.

Sacks NC, Cyr P, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Burden of acute myeloid leukemia (AML) among older newly-diagnosed patients. Blood 128(22):4780; doi: 10.1182/blood.V128.22.4780.4780.

View Abstract

Sacks NC, Noone J, Cyr PL, Miller DJ, Chiarella MT, Louie AC. 2016. Hospitalizations for older patients with acute myeloid leukemia (AML): Inpatient treatment is intensive and costly. Value in Health 19(3):A246; doi: 10.1016/j.jval.2016.03.1051.

View Abstract

Sacks NC, Sharma A, Cyr PL, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Outcomes for older patients with acute myeloid leukemia (AML): Multiple hospitalizations and high mortality rates. Value in Health 19(7):A611; doi: 10.1016/j.jval.2016.09.1523.

View Abstract